Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

(2012) M. S. Czuczman et al.   BLOOD

Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma

(2012) Myron S. Czuczman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia

(2011) Ginah Nightingale   ANNALS OF PHARMACOTHERAPY

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

(2011) W. G. Wierda et al.   BLOOD

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

(2011) W. G. Wierda et al.   BLOOD

Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia

(2011) John L Reagan et al.   Expert Review of Anticancer Therapy

Ofatumumab in the treatment of low-grade non-Hodgkin’s lymphomas and chronic lymphocytic leukemia

(2011) Celeste Bello et al.   Expert Review of Clinical Immunology

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

(2010) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

(2010) Tadeusz Robak et al.   BIODRUGS

Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia

(2010) Susan O'Brien et al.   Clinical Lymphoma Myeloma & Leukemia

Ofatumumab

(2010) Mark Sanford et al.   DRUGS

Ofatumumab, a human anti-CD20 monoclonal antibody

(2010) Anders Österborg   EXPERT OPINION ON BIOLOGICAL THERAPY

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies

(2010) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

The future of CD20 monoclonal antibody therapy in B-cell malignancies

(2010) Myron S. Czuczman et al.   LEUKEMIA & LYMPHOMA

Ofatumumab

(2010) Bodi Zhang   mAbs

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD